Alkem Laboratories has announced two significant acquisitions worth nearly Rs 200 crore to strengthen its presence in the Indian pharmaceutical and medical devices market. The acquisitions include a 100% stake in Adroit Biomed, a skincare-focused pharmaceutical company, and 100% stake in Bombay Ortho Industries, a manufacturer of orthopedic implants.

Key Highlights:
Acquisition of Adroit Biomed:

• Alkem Labs will buy Adroit Biomed for Rs 140 crore.

• This will enable Alkem to diversify its portfolio and increase its market share in the dermatology and cosmetology segments.

Acquisition of Bombay Ortho Industries:

• Alkem MedTech, a subsidiary of Alkem Labs, will buy Bombay Ortho Industries for Rs 147 crore.

• The acquisition is in line with Alkem's MedTech strategy to capitalise on growing demand for orthopedic implants in India.

MedTech Focus Strategy:
The acquisitions signify Alkem's increased focus on the fast-growing MedTech sector in India, aiming to provide high-quality medical devices and implants.

Statements from Leaders or Officials:

• BN Singh, Chairman, Alkem Labs:

“The acquisition of Adroit will enable Alkem to diversify its portfolio, enhance market penetration, and strengthen our presence in the growing segments of dermatology and cosmetology. Our investment in Bombay Ortho is aligned with our strategy for MedTech in India.”

• Sandeep Singh, Managing Director, Alkem Labs:

“MedTech is a fast-growing space in India, and the patient need for quality products is high. Through our acquisitions in the medical devices segment, we aim to meet the growing demand for implants in India.”These strategic acquisitions will allow Alkem Labs to expand its market share in both the pharmaceutical and MedTech sectors. By entering the skincare and orthopedic implant markets, Alkem is positioning itself to capitalize on growing patient demands and market opportunities in India’s healthcare landscape. The deals reflect the company’s commitment to diversification and its focus on innovation in medical devices.